Page last updated: 2024-08-23

torsemide and bumetanide

torsemide has been researched along with bumetanide in 26 studies

Research

Studies (26)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's5 (19.23)18.2507
2000's11 (42.31)29.6817
2010's7 (26.92)24.3611
2020's3 (11.54)2.80

Authors

AuthorsStudies
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Andricopulo, AD; Moda, TL; Montanari, CA1
Lombardo, F; Obach, RS; Waters, NJ1
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV1
Campillo, NE; Guerra, A; Páez, JA1
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV1
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Delarge, J; Ferrandi, M; Ferrari, P; Masereel, B; Parenti, P; Pirotte, B; Schynts, M1
Brater, DC1
Brater, DC; Gehr, TW; Kramer, WG; Matzke, GR; Rudy, DW; Sica, DA1
Silke, B1
Chen, BP1
Kelso, E; McDermott, B; Silke, B; Spiers, P1
Bard, RL; Bleske, BE; Nicklas, JM1
Eshaghian, S; Fonarow, GC; Horwich, TB1
Chuen, MJ; MacFadyen, RJ1
Brockmöller, J; Meineke, I; Nürnberg, P; Schirmer, M; Sehrt, D; Toliat, MR; Tzvetkov, M; Vormfelde, SV1
Cantarovich, F; Hoste, E; Mehta, RL; Murray, P; Shaw, A1
Baughman, KL; Desai, AS; Fang, JC; Givertz, MM; Lewis, EF; Mielniczuk, LM; Nohria, A; Stevenson, LW; Tsang, SW1
Bloomfield, DM; Cleland, JG; Cotter, G; Damman, K; Davison, B; Dittrich, HC; Fiuzat, M; Givertz, MM; Hillege, HL; Massie, BM; Metra, M; O'Connor, CM; Ponikowski, P; Teerlink, JR; Valente, MA; Van Veldhuisen, DJ; Voors, AA1
Brockmöller, J; Dalila, N; Haubrock, M; Schirmer, M; Tzvetkov, MV; Vormfelde, SV1
Agewall, S; Atar, D; Clark, AL; Cleland, JGF; Frankenstein, L; Fröhlich, H; Goode, K; Grundtvig, M; Hole, T; Katus, HA; Kazmi, S; Schellberg, D; Seiz, M; Täger, T1
Gramer, M; Hampel, P; Löscher, W; Römermann, K1
Gailus, B; Gericke, B; Hampel, P; Johne, M; Kaczmarek, E; Löscher, W; Römermann, K1
Gramer, M; Kirchhoff, L; Löscher, W; Schmidt, R; Welzel, B1

Reviews

5 review(s) available for torsemide and bumetanide

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
Clinical pharmacology of loop diuretics.
    Drugs, 1991, Volume: 41 Suppl 3

    Topics: Bumetanide; Diuretics; Furosemide; Humans; Sulfonamides; Torsemide

1991
Central hemodynamic effects of diuretic therapy in chronic heart failure.
    Cardiovascular drugs and therapy, 1993, Volume: 7 Suppl 1

    Topics: Bumetanide; Cardiac Output; Diuresis; Diuretics; Furosemide; Heart Failure; Hemodynamics; Humans; Muzolimine; Plasma Volume; Sulfonamides; Torsemide

1993
Loop diuretics: comparison of torsemide, furosemide, and bumetanide.
    Connecticut medicine, 1996, Volume: 60, Issue:6

    Topics: Bumetanide; Diuretics; Furosemide; Humans; Sulfonamides; Torsemide

1996
Food: an unrecognized source of loop diuretic resistance.
    Pharmacotherapy, 2004, Volume: 24, Issue:5

    Topics: Administration, Oral; Area Under Curve; Bumetanide; Clinical Trials as Topic; Diuresis; Diuretics; Food; Furosemide; Humans; Intestinal Absorption; Sulfonamides; Torsemide

2004

Trials

4 trial(s) available for torsemide and bumetanide

ArticleYear
The pharmacodynamics of intravenous and oral torsemide in patients with chronic renal insufficiency.
    Clinical pharmacology and therapeutics, 1994, Volume: 56, Issue:1

    Topics: Administration, Oral; Bumetanide; Diuretics; Double-Blind Method; Furosemide; Humans; Injections, Intravenous; Kidney Failure, Chronic; Sulfonamides; Torsemide

1994
Genetic variation in the renal sodium transporters NKCC2, NCC, and ENaC in relation to the effects of loop diuretic drugs.
    Clinical pharmacology and therapeutics, 2007, Volume: 82, Issue:3

    Topics: Adult; Bumetanide; Cross-Over Studies; Diuretics; Epithelial Sodium Channels; Furosemide; Genotype; Haplotypes; Humans; Kidney; Male; Middle Aged; Phenotype; Polymorphism, Genetic; Potassium; Receptors, Drug; Sodium-Potassium-Chloride Symporters; Solute Carrier Family 12, Member 1; Solute Carrier Family 12, Member 3; Sulfonamides; Symporters; Thiazides; Torsemide

2007
Diuretic response in acute heart failure: clinical characteristics and prognostic significance.
    European heart journal, 2014, May-14, Volume: 35, Issue:19

    Topics: Acute Disease; Aged; Analysis of Variance; Atherosclerosis; Bumetanide; Diabetes Complications; Diuretics; Dose-Response Relationship, Drug; Drug Resistance; Dyspnea; Female; Furosemide; Heart Failure; Humans; Hypotension; Male; Patient Readmission; Renal Insufficiency; Sulfonamides; Torsemide; Treatment Outcome; Weight Loss; Xanthines

2014
Impact of mineralocorticoid receptor polymorphisms on urinary electrolyte excretion with and without diuretic drugs.
    Pharmacogenomics, 2015, Volume: 16, Issue:2

    Topics: Adolescent; Adult; Bumetanide; Cross-Over Studies; Diuretics; Electrolytes; Furosemide; Genetic Association Studies; Humans; Hydrochlorothiazide; Male; Middle Aged; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Potassium; Receptors, Mineralocorticoid; Single-Blind Method; Sodium Chloride; Sulfonamides; Torsemide; Triamterene; Young Adult

2015

Other Studies

17 other study(ies) available for torsemide and bumetanide

ArticleYear
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
Hologram QSAR model for the prediction of human oral bioavailability.
    Bioorganic & medicinal chemistry, 2007, Dec-15, Volume: 15, Issue:24

    Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship

2007
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Physicochemical determinants of human renal clearance.
    Journal of medicinal chemistry, 2009, Aug-13, Volume: 52, Issue:15

    Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight

2009
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
    European journal of medicinal chemistry, 2010, Volume: 45, Issue:3

    Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical

2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
    Journal of medicinal chemistry, 2010, Feb-11, Volume: 53, Issue:3

    Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations

2010
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
    Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:12

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship

2012
Na+,2Cl-,K+ cotransport system as a marker of antihypertensive activity of new torasemide derivatives.
    European journal of pharmacology, 1992, Sep-04, Volume: 219, Issue:3

    Topics: Animals; Blood Pressure; Bumetanide; Chlorine; Diuretics; Erythrocytes; Hypertension; In Vitro Techniques; Kidney Medulla; Male; Potassium; Rats; Rats, Inbred SHR; Rats, Inbred Strains; Rubidium Radioisotopes; Sodium; Structure-Activity Relationship; Sulfonamides; Torsemide

1992
Positive effect of bumetanide on contractile activity of ventricular cardiomyocytes.
    European journal of pharmacology, 2000, Jul-14, Volume: 400, Issue:1

    Topics: Animals; Bumetanide; Calcium Channels, L-Type; Cardiotonic Agents; Diuretics; Furosemide; Heart Ventricles; Isoproterenol; Male; Myocardial Contraction; Rabbits; Sulfonamides; Torsemide

2000
Relation of loop diuretic dose to mortality in advanced heart failure.
    The American journal of cardiology, 2006, Jun-15, Volume: 97, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bumetanide; California; Creatinine; Diuretics; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Furosemide; Heart Failure; Humans; Male; Middle Aged; Prognosis; Stroke Volume; Sulfonamides; Survival Analysis; Torsemide

2006
Dose-dependent association between use of loop diuretics and mortality in advanced systolic heart failure.
    The American journal of cardiology, 2006, Nov-15, Volume: 98, Issue:10

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bumetanide; California; Creatinine; Diuretics; Dose-Response Relationship, Drug; Female; Furosemide; Heart Failure; Humans; Male; Middle Aged; Prognosis; Stroke Volume; Sulfonamides; Survival Analysis; Torsemide; Ventricular Dysfunction, Left

2006
Pharmacologic approaches for volume excess in acute kidney injury (AKI).
    The International journal of artificial organs, 2008, Volume: 31, Issue:2

    Topics: Acute Kidney Injury; Ascites; Bumetanide; Diuretics; Fluid Therapy; Furosemide; Heart Failure; Hepatorenal Syndrome; Humans; Kidney; Kidney Failure, Chronic; Liver Cirrhosis; Natriuretic Agents; Nephrotic Syndrome; Renal Replacement Therapy; Sodium Potassium Chloride Symporter Inhibitors; Sulfonamides; Torsemide; Ultrafiltration; Water-Electrolyte Imbalance

2008
The association between high-dose diuretics and clinical stability in ambulatory chronic heart failure patients.
    Journal of cardiac failure, 2008, Volume: 14, Issue:5

    Topics: Ambulatory Care; Ambulatory Care Facilities; Antihypertensive Agents; Bumetanide; Comorbidity; Diuretics; Female; Furosemide; Health Status Indicators; Heart Failure; Humans; Male; Middle Aged; Prospective Studies; Sulfonamides; Torsemide; Treatment Outcome

2008
Comparative effectiveness of loop diuretics on mortality in the treatment of patients with chronic heart failure - A multicenter propensity score matched analysis.
    International journal of cardiology, 2019, 08-15, Volume: 289

    Topics: Aged; Blood Pressure; Bumetanide; Cause of Death; Europe; Female; Follow-Up Studies; Furosemide; Heart Failure; Humans; Male; Middle Aged; Propensity Score; Retrospective Studies; Sodium Potassium Chloride Symporter Inhibitors; Stroke Volume; Survival Rate; Torsemide; Treatment Outcome; Ventricular Function, Left

2019
The search for brain-permeant NKCC1 inhibitors for the treatment of seizures: Pharmacokinetic-pharmacodynamic modelling of NKCC1 inhibition by azosemide, torasemide, and bumetanide in mouse brain.
    Epilepsy & behavior : E&B, 2021, Volume: 114, Issue:Pt A

    Topics: Animals; Brain; Bumetanide; Endothelial Cells; Humans; Mice; Seizures; Sodium Potassium Chloride Symporter Inhibitors; Solute Carrier Family 12, Member 2; Sulfanilamides; Torsemide

2021
Effects of the NKCC1 inhibitors bumetanide, azosemide, and torasemide alone or in combination with phenobarbital on seizure threshold in epileptic and nonepileptic mice.
    Neuropharmacology, 2021, 03-01, Volume: 185

    Topics: Animals; Anticonvulsants; Bumetanide; Drug Therapy, Combination; Epilepsy; Female; Mice; Phenobarbital; Pilocarpine; Seizures; Sodium Potassium Chloride Symporter Inhibitors; Solute Carrier Family 12, Member 2; Sulfanilamides; Torsemide; Treatment Outcome

2021
The loop diuretic torasemide but not azosemide potentiates the anti-seizure and disease-modifying effects of midazolam in a rat model of birth asphyxia.
    Epilepsy & behavior : E&B, 2023, Volume: 139

    Topics: Animals; Asphyxia; Bumetanide; Diuretics; Epilepsy; Furosemide; Rats; Sodium Potassium Chloride Symporter Inhibitors; Solute Carrier Family 12, Member 2; Torsemide

2023